@article{ATM25318,
author = {Lingwei Wang and Mengjie Feng and Qiuwen Li and Chen Qiu and Rongchang Chen},
title = {Advances in nanotechnology and asthma},
journal = {Annals of Translational Medicine},
volume = {7},
number = {8},
year = {2019},
keywords = {},
abstract = {According to the World Health Organization, Asthma is the fastest-growing disease in the world alongside HIV/AIDS, and its socioeconomic burden exceeds the sum of HIV/AIDS and tuberculosis. Its high disability and mortality rates have become serious social and public health concerns. Asthma is a heterogeneous disease in which genetic polymorphisms interact with the environmental factors. While no specific treatment has been available for asthma due to its complex pathogenesis, the advances in nanotechnology have brought new hope for the early diagnosis, treatment, and prevention of asthma. Nanotechnology can achieve targeted delivery of drugs or genes, reduce toxic effects, and improve drug bioavailability. The nano-modifications of drugs and the development of new nano-drugs have become new research directions. Studies have demonstrated the safety and effectiveness of nanocarriers. However, many challenges still need to be overcome before nanotherapy can be applied in clinical practice. In this article we review the new research highlights in this area, with an attempt to explore the great potential and feasibility of nanotechnology in treating asthma.},
issn = {2305-5847}, url = {https://atm.amegroups.org/article/view/25318}
}